PetVivo names Jaime Pickett to board
PetVivo replaces a resigning director with experienced veterinary executive Jaime K. Pickett while maintaining a six-member Board.
Rhea-AI Filing Summary
PetVivo Holdings, Inc. (PETV) reported a Board change effective September 22, 2026, with the resignation of director Diane Levitan, which the company states did not result from any disagreement regarding operations, policies or practices. The Board simultaneously appointed Jaime K. Pickett, DVM, MBA, to fill the vacancy, keeping the Board at six directors. Dr. Pickett is a veterinary healthcare executive and entrepreneur with more than 20 years of experience in animal health, multi-site operations, corporate strategy and product commercialization, including leadership over more than 55 pet resorts and veterinary hospitals and teams of over 100 veterinary professionals. She will initially serve as a non-employee director with compensation consistent with other non-employee directors, and the company notes there are no related-party transactions or family relationships requiring disclosure.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
emerging biomedical device company medical
intra-articular injection medical
OsteoCushion technology medical
telehealth implementation technical
forward-looking statements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Board change did PetVivo Holdings, Inc. (PETV) announce on September 22, 2026?
Did Diane Levitan resign from PETV’s Board due to a disagreement with the company?
Who is Jaime K. Pickett and what experience does she bring to PETV’s Board?
How long will Jaime K. Pickett serve on the PetVivo (PETV) Board under this appointment?
What compensation will Jaime K. Pickett receive as a PetVivo (PETV) director?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQX |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Diane Levitan
Effective September 22, 2026, Diane Levitan resigned as a member of the Board of Directors (the “Board”) of PetVivo Holdings, Inc., a Nevada corporation (the “Company”). Dr. Levitan’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Board expresses its appreciation to Dr. Levitan for her leadership, guidance and contributions during her tenure on the Board.
Appointment of Jaime K. Pickett
Effective September 22, 2026, the Board appointed Jaime K. Pickett as a director of the Company to fill the vacancy created by Dr. Levitan’s resignation, thereby maintaining the size of the Board at six directors. Dr. Pickett will serve until the next annual meeting of shareholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
Dr. Pickett is a veterinary healthcare executive, entrepreneur, multi-unit franchisee and board leader with more than 20 years of experience spanning animal health, multi-site operations, corporate strategy, business development, clinical innovation, product commercialization and organizational growth. She currently serves as Chief Medical Officer of EQUUSIR USA and as Advising Chief Medical Officer and a board member of Alexander International Innovations, where she provides clinical, regulatory, commercialization and strategic guidance for emerging medical and animal-health technologies. She also serves on the Board of Chief Veterinary Medical Officers, a professional organization of senior veterinary executives, and is a Scenthound multi-unit franchisee.
From 2023 to 2026, Dr. Pickett held executive leadership roles with Hannah Pet Hospitals, including Chief Executive Officer, President, board member and Chief Strategy Officer. From 2017 to 2022, she served as Chief Veterinary Officer and Senior Vice President of Pet Paradise and as Chief Operating Officer of its subsidiary, NewDay Veterinary Care. In these executive leadership roles, she led veterinary and operational strategy across more than 55 pet resorts and veterinary hospitals in over 15 states, directed teams of more than 100 veterinary professionals, and was instrumental to the organization’s strong enterprise revenue. Her experience also includes veterinary practice ownership, multi-site expansion, mergers and acquisitions evaluation, and telehealth implementation.
Dr. Pickett earned her Doctor of Veterinary Medicine from the University of Florida College of Veterinary Medicine, an MBA from St. George’s University and a Bachelor of Arts from Johns Hopkins University, with minors in Psychology and Computer Science. She also completed the Global C-Suite Program through Wharton Executive Education at the University of Pennsylvania. Her governance and professional service include service on the Board of Directors of The Doorways and nine years on the University of Florida College of Veterinary Medicine Admissions Committee. She is a lifetime member of the University of Florida College of Veterinary Medicine Dean’s Circle of Excellence and a member of the American Veterinary Medical Association.
Dr. Pickett’s extensive veterinary healthcare and executive leadership experience, together with her background in multi-site operations, corporate strategy, business development and animal-health technology commercialization, were material factors in the Board’s determination that she is qualified to serve as a director of the Company.
Dr. Pickett will initially serve as a non-employee director and receive compensation consistent with that of the Company’s other non-employee directors, prorated for her period of service. The Company’s non-employee director compensation program is described in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2025. Her compensation for Board service may be adjusted by the Board in connection with any subsequent employment by the Company or one of its subsidiaries.
There are no arrangements or understandings between Dr. Pickett and any other persons pursuant to which she was selected as a director of the Company and there are no transactions or proposed transactions in which Dr. Pickett has a direct or indirect interest requiring disclosure under Item 404(a) of Regulation S-K or Item 5.02(d) of Form 8-K. Dr. Pickett does not have any family relationship with any of the Company’s directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer.
At ther time, Dr. Pickett has not been appointed to any committees.
The press release announcing her appointment is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. | |
99.1 104 |
Press Release dated September 22, 2026 Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| PETVIVO HOLDINGS, INC. | ||
| Date: September 22, 2026 | By: | /s/ John Lai |
| Name: | John Lai | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
5151 Edina Industrial Blvd., Suite 575, Minneapolis, MN 55439 | (952) 405-6216 | www.petvivo.com
PRESS RELEASE:
Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors
MINNEAPOLIS, MN, US, September 22, 2026 — PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, today announced the appointment of Jaime K. Pickett, DVM, MBA, to its Board of Directors, effective September 22, 2026.
“We are pleased to welcome Dr. Jaime Pickett to PetVivo’s Board of Directors,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Jaime brings a valuable combination of veterinary expertise, executive leadership and experience growing veterinary care organizations. Her understanding of clinical practice, hospital operations and animal-health technology will provide an important perspective as we work to expand product adoption, strengthen relationships with veterinarians and pursue opportunities for sustainable growth.”
Dr. Pickett is a veterinary healthcare executive, entrepreneur and board leader with more than 20 years of experience in animal health, multi-site operations, corporate strategy, business development and product commercialization. She currently serves as Chief Medical Officer of EQUUSIR USA and as Advising Chief Medical Officer and a board member of Alexander International Innovations, providing clinical, regulatory, commercialization and strategic guidance for emerging medical and animal-health technologies. She also serves on the Board of Chief Veterinary Medical Officers and is a Scenthound multi-unit franchisee.
From 2023 to 2026, Dr. Pickett held executive leadership roles with Hannah Pet Hospitals, including Chief Executive Officer, President, board member and Chief Strategy Officer. From 2017 to 2022, she served as Chief Veterinary Officer and Senior Vice President of Pet Paradise and as Chief Operating Officer of its subsidiary, NewDay Veterinary Care. In these executive leadership roles, she led veterinary and operational strategy across more than 55 pet resorts and veterinary hospitals in over 15 states, directed teams of more than 100 veterinary professionals, and was instrumental to the organization’s strong enterprise revenue. Her experience also includes veterinary practice ownership, multi-site expansion, mergers and acquisitions evaluation, and telehealth implementation.
Dr. Pickett earned her Doctor of Veterinary Medicine from the University of Florida College of Veterinary Medicine, an MBA from St. George’s University and a Bachelor of Arts from Johns Hopkins University. She also completed the Global C-Suite Program through Wharton Executive Education at the University of Pennsylvania. She is a member of the American Veterinary Medical Association and served for nine years on the University of Florida College of Veterinary Medicine Admissions Committee.
“I am excited to join PetVivo’s Board and contribute both a veterinarian’s perspective and my experience building and leading animal-health businesses,” said Dr. Pickett. “Bringing new technologies into veterinary practice requires an understanding of clinical needs, practice operations and the support veterinary teams need to evaluate and adopt them. I look forward to working with John and the team to help advance PetVivo’s commercial strategy, strengthen connections with the veterinary community and create long-term value for shareholders.”
Dr. Pickett fills the vacancy created by Diane Levitan’s resignation, effective September 22, 2026. The Board thanks Dr. Levitan for her leadership, guidance and contributions during her tenure. Following these changes, the Board continues to consist of six directors.
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product, SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
| 2 |